Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer Inc. today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President ...

Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its ...

This agreement solidifies Pfizer at the forefront of innovative cancer research and further enhances the company’s robust oncology pipeline. “We are excited to contribute our significant expertise and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

(Reuters) -Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and development, as the drugmaker faces pressure from investors to produce ...

Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

Merck MRK and Pfizer PFE are leading pharmaceutical companies with strong product and pipeline portfolios in oncology. Both companies also have presences in vaccines, neuroscience, and immunology ...

Paid Content from Pfizer Megan O’Meara, M.D., head of early-stage development at Pfizer Oncology, is deeply committed to scientific innovation, mentorship, and breaking barriers for the next ...

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoffeffective January 1, 2025.